1.       Lu LJ et al. Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma. Yale J Biol Med. 2017 Mar;90(1):111-118.

2.       Harasymowycz P et al. Medical Management of Glaucoma in the 21st Century from a Canadian Perspective. J Ophthalmol. 2016; 2016:6509809. Epub 2016 Nov 8.

3.       European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4rd Edition. Savona, Italy: PubliComm; 2014.

4.       American Academy of Ophthalmology Glaucoma Panel, “Preferred Practice Pattern_ Guidelines,” Primary Open-Angle Glaucoma,

5.       F. A. Medeiros, R. Lisboa, R. N. Weinreb, J. M. Liebmann, C. Girkin, and L. M. Zangwill, “Retinal ganglion cell count estimates associated with early development of visual field defects in glaucoma,” Ophthalmology. 2013; vol. 120, no. 4, pp. 736–744.

6.       G. Holl´o, F. Topouzis, and R. D. Fechtner, “Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice,” Expert Opinion on Pharmacotherapy. 2014; vol. 15, no. 12, pp. 1737–1747.

7.       A. Doozandeh and S. Yazdani, “Neuroprotection in glaucoma”. Journal of Ophthalmic and Vision Research. 2016; vol. 11, no. 2, pp.209–220.

8.       H. Tanihara, T. Inoue, T. Yamamoto et al., “One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension,” Acta Ophthalmologica. 2016; vol. 94, no. 1, pp. e26–e34.

9.       R. Agarwal and P. Agarwal, “Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways,” Expert Opinion on Therapeutic Targets. 2014; vol. 18, no. 5, pp. 527–539.

10.    C. A. Rasmussen, P. L. Kaufman, R. Ritch, R. Haque, R. K.Brazzell, and J. L. Vittitow, “Latrunculin B reduces intraocular pressure in human ocular hypertension and primary open angle glaucoma,” Translational Vision Science & Technology. 2014; vol.3, no. 5, article 1.

11.    Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study. Ophthalmology. 2016; 123:965-973.

4ª Edição - Maio 2017